Chronic cyclosporin A therapy in rats

Area of Science:

• Pharmacology
• Toxicology
• Immunosuppression

Background:

• Cyclosporin A (CsA) is a vital immunosuppressant drug.
• Understanding its long-term pharmacokinetics and toxicity is crucial for effective clinical use.
• Rodent models are frequently used to study drug behavior.

Purpose of the Study:

• To investigate the pharmacokinetics and toxicity of chronic subcutaneous cyclosporin A administration in rats.
• To evaluate the impact of different dosing regimens (daily vs. alternate-day) on CsA blood levels and toxicity.
• To assess the drug accumulation and depot effect of CsA in a long-term study.

Main Methods:

• Ninety Lewis rats received subcutaneous CsA (5 mg/kg/day) for up to 30 weeks.
• Two dosing groups were established: daily dosing for 12 weeks, then cessation; daily dosing for 18 weeks, followed by alternate-day dosing until week 30.
• Whole blood CsA levels were measured using radioimmunoassay; body weight and animal survival were monitored.
• Pharmacokinetic parameters, including trough levels and drug elimination half-life, were analyzed.

Main Results:

• Daily CsA dosing resulted in significantly elevated trough blood levels (>1,600 µg/L), leading to chronic systemic toxicity, weight loss, and mortality.
• Switching to alternate-day dosing reduced mean trough levels (1,311 µg/L) and decreased observed toxicity.
• Subcutaneous administration demonstrated a depot effect, maintaining drug levels over 48 hours and showing slow drug level decline (15 days) post-treatment cessation.

Conclusions:

• Chronic daily CsA administration via subcutaneous route can lead to drug accumulation and significant toxicity in rats.
• Alternate-day dosing can mitigate CsA toxicity by reducing blood drug concentrations.
• Monitoring body weight and blood CsA levels is essential in rodent studies involving CsA to prevent adverse effects and guide dose adjustments.